Pharmaceuticals

Uncommon Productions' 'Cracking the Code' earns top honors, celebrating the biotech revolution and the power of scientific ingenuity.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

Sensorium Therapeutics advances SNTX-2643, a novel anxiety drug, while adding a new CMO and an expert advisory board to guide its clinical journey.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

Dutch CDMO Intravacc's new French tax credit approval offers a major financial boost for biotech partners, aiming to accelerate vaccine R&D in Europe.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Wellness brand Le-Vel is launching a telehealth service for prescription peptides, blurring the lines between direct sales and mainstream medicine.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Positive Phase 3 data for oral drug filgotinib offers new hope for thousands of axial spondyloarthritis patients who fail to respond to current therapies.

Prezent Vivo and Nested Knowledge partner to close the 'insight-to-action' gap, delivering AI-powered intelligence to pharma teams at unprecedented speed.

With new funding from Bregal Sagemount, LSPedia is set to advance its AI tools, moving beyond compliance to build a smarter, safer pharma supply chain.

ValGenesis's upcoming event explores AI's pivotal role in pharma validation, charting a course from digital systems to intelligent, compliant operations.

A new analysis reveals most insured Americans can't access obesity drugs, even with coverage, due to restrictive insurance hurdles.

A new global repository by Zifo and the Pistoia Alliance aims to standardize biological data, promising to accelerate drug discovery and fix costly data silos.

A new report reveals Europe's medically-focused cannabis market is finally waking, creating a new global blueprint but also intense competition and price wars.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

Colombia invests $260M to regain vaccine independence through a landmark tech transfer deal with South Korea's SK bioscience. A new chapter begins.

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.